insights_auto
Why is D4S up 2.23%?
Dive Deeperchevron_right
D4S:FRA
Daiichi Sankyo Co Ltd
€14.78
arrow_upward
+2.23%(+0.32) 1D
Oct 15, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for D4S...
Open
€14.78
High
€14.78
Low
€14.78
Mkt. cap
31.35B
Avg. vol.
60.00
Volume
0.00
52-wk high
€23.75
52-wk low
€12.69
No. of employees
20K
Open
€14.78
High
€14.78
Low
€14.78
Mkt. cap
31.35B
Avg. vol.
60.00
Volume
0.00
52-wk high
€23.75
52-wk low
€12.69
No. of employees
20K
News stories
From web sources and news partners
ad-hoc-news.de
·
39 minutes ago
Nomura keeps JPY 3,800.00 target for Daiichi Sankyo stock
Profile
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
About Daiichi Sankyo Co Ltd
CEOHiroyuki Okuzawa
Employees20.2K
FoundedSep 28, 2005
HeadquartersChuo City, Tokyo, Japan
Sector-
Websitedaiichisankyo.co.jp